Are we any closer to beating the biofilm: Novel methods of biofilm control

Current Opinion in Infectious Diseases

Volumn 23, Issue 6, 2010, Pages 560-566

  Ramage, Gordon ^a   Culshaw, Shauna ^a   Jones, Brian ^b   Williams, Craig ^c  

^a GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

antimicrobial; biofilm; disruption; management

Indexed keywords

ACETYLCYSTEINE; ADRENOMEDULLIN; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ATRIAL NATRIURETIC FACTOR; CASPOFUNGIN; CHLORHEXIDINE; CIPROFLOXACIN; ENDOTHELIN 1; FLUCLOXACILLIN; MICAFUNGIN; POVIDONE IODINE; PROCALCITONIN; PROTON PUMP INHIBITOR; SILVER; TIGECYCLINE; VASOPRESSIN;

ADVERSE OUTCOME; ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; BIOFILM; CANDIDIASIS; CATHETER INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC WOUND; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONFOCAL LASER MICROSCOPY; CYSTIC FIBROSIS; DEBRIDEMENT; DECUBITUS; DENTAL CARIES; DEVICE INFECTION; DIABETIC FOOT; DRUG EFFICACY; ENDOTRACHEAL TUBE; ESCHERICHIA COLI; FOOT ULCER; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HUMAN; LEG ULCER; MATERIAL COATING; MOLECULAR BIOLOGY; MOUTH CAVITY; MUCOCUTANEOUS CANDIDIASIS; NONHUMAN; PERIODONTAL DISEASE; PERIODONTITIS; PNEUMONIA; QUORUM SENSING; REVIEW; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; URINARY CATHETER; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION;

ANTI-INFECTIVE AGENTS; BACTERIA; BIOFILMS; CATHETERS; DEVICE REMOVAL; FUNGI; GASTROINTESTINAL TRACT; HUMANS; MOUTH; PROSTHESES AND IMPLANTS; RESPIRATORY SYSTEM; URINARY TRACT; WOUNDS AND INJURIES;

EID: 78349261215     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833e5850     Document Type: Review

References (47)

1. Gardner SE, Frantz RA, Doebbeling BN. The validity of the clinical signs and symptoms used to identify localized chronic wound infection. Wound Repair Regen 2001; 9:178-186.
2. Ramage G, Mowat E, Jones B, et al. Our current understanding of fungal biofilms. Crit Rev Microbiol 2009; 35:340-355.
3. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358:135-138.
4. Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis 2002; 8:881-890.
5. Hoiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010; 35:322-332.
6. Kirketerp-Moller K, Jensen PO, Fazli M, et al. Distribution, organization, and ecology of bacteria in chronic wounds. J Clin Microbiol 2008; 46:2717-2722.
7. James GA, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. Wound Repair Regen 2008; 16:37-44.
8. Wolcott RD, Gontcharova V, Sun Y, et al. Bacterial diversity in surgical site infections: notjust aerobic cocci any more. J Wound Care 2009; 18:317-323.
9. Fazli M, Bjarnsholt T, Kirketerp-Moller K, et al. Nonrandom distribution of Pseudomonas aeruginosa and Staphylococcus aureus in chronic wounds. J Clin Microbiol 2009; 47:4084-4089.
10. Hill KE, Malic S, McKee R, et al. An in vitro model of chronic wound biofilmsto test wound dressings and assess antimicrobial susceptibilities. J Antimicrob Chemother 2010; 65:1195-1206.
11. Smith K, Gould KA, Ramage G, et al. Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54:380-387.
12. Wolcott RD, Kennedy JP, Dowd SE. Regular debridement is the main tool for maintaining a healthy wound bed in most chronic wounds. J Wound Care 2009; 18:54-56.
13. Iwase T, Uehara Y, Shinji H, et al. Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 2010; 465:346-349.
14. Seymour GJ, Ford PJ, Cullinan MP, et al. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect 2007; 13 (Suppl 4): 3-10.
15. Dashper SG, Ang CS, Liu SW, et al. Inhibition of Porphyromonas gingivalis biofilm by oxantel. Antimicrob Agents Chemother 2010; 54:1311-1314.
16. Liu PF, Shi W, Zhu W, et al. Vaccination targeting surface FomA of Fusobacterium nucleatum against bacterial co-aggregation: implication for treatment of periodontal infection and halitosis. Vaccine 2010; 28: 3496-3505.
17. ZahradnikRT, Magnusson I, Walker C, et al. Preliminary assessment of safety and effectiveness in humans of ProBiora3, a probiotic mouthwash. J Appl Microbiol 2009; 107:682-690.
18. Novak EA, Shao H, Daep CA, et al. Autoinducer-2 and QseC control biofilm formation and in vivo virulence of Aggregatibacter actinomycetemcomitans. Infect Immun 2010; 78:2919-2926.
19. Mojon P, Bourbeau J. Respiratory infection: how important is oral health? Curr Opin Pulm Med 2003; 9:166-170.
20. Scannapieco FA, Yu J, Raghavendran K, et al. A randomized trial of chlorhex-idine gluconate on oral bacterial pathogens in mechanically ventilated patients. Crit Care 2009; 13:R117.
21. Chan EY, Ruest A, Meade MO, et al. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. BMJ 2007; 334:889.
22. Kollef MH, Afessa B, Anzueto A, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 2008; 300:805-813.
23. Afessa B, Shorr AF, Anzueto AR, et al. Association between a silver-coated endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia. Chest 2010; 137:1015-1021.
24. Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010; 14:R106.
25. Parker D,Soong G, Planet P, et al. The NanA neuraminidase of Streptococcus pneumoniae is involved in biofilm formation. Infect Immun 2009; 77:3722-3730.
26. Cammarota G, Branca G, Ardito F, et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol 2010 [Epub ahead of print].
27. Zhao T, Liu Y. N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiol 2010; 10:140.
28. Zaric S, Bojic B, Jankovic L, et al. Periodontal therapy improves gastric Helicobacter pylori eradication. J Dent Res 2009; 88:946-950.
29. Crawford RW, Rosales-Reyes R, Ramirez-Aguilar Mde L, et al. Gallstones play a significant role in Salmonella spp. gallbladder colonization and carriage. Proc Natl Acad Sci USA 2010; 107:4353-4358.
30. Butler MT, Wang Q, Harshey RM. Cell density and mobility protect swarming bacteria against antibiotics. Proc Natl Acad Sci USA 2010; 107:3776-3781.
31. Lowery CA, Park J, Kaufmann GF, et al. An unexpected switch in the modulation of AI-2-based quorum sensing discovered through synthetic 4,5-dihydroxy-2,3-pentanedione analogues. J Am Chem Soc 2008; 130:9200-9201.
32. Frank DN, Wilson SS, St Amand AL, et al. Culture-independent microbiological analysis of foley urinary catheter biofilms. PLoS One 2009; 4:e7811.
33. Wang X, Lunsdorf H, Ehren I, et al. Characteristics of biofilms from urinary tract catheters and presence of biofilm-related components in Escherichia coli. Curr Microbiol 2010; 60:446-453.
34. Blango MG, Mulvey MA. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 2010; 54:1855-1863.
35. Carson L, Gorman SP, Gilmore BF. The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol Med Microbiol 2010 [Epub ahead of print].
36. Hancock V, Dahl M, Klemm P. Abolition of biofilm formation in urinary tract Escherichia coli and Klebsiella isolates by met al interference through competition for fur. Appl Environ Microbiol 2010; 76:3836-3841.
37. Cegelski L, Pinkner JS, Hammer ND, et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol 2009; 5:913-919.
38. Agostinho A, James G, Wazni O, et al. Inhibition of Staphylococcus aureus biofilms by a novel antibacterial envelope for use with implantable cardiac devices. Clin Transl Sci 2009; 2:193-198.
39. Neut D, Kluin OS, Crielaard BJ, et al. A biodegradable antibiotic delivery system based on poly-(trimethylene carbonate) for the treatment of osteomyelitis. Acta Orthop 2009; 80:514-519.
40. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45.
41. Lazzell AL, Chaturvedi AK, Pierce CG, et al. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother 2009; 64:567-570.
42. Mukherjee PK, Long L, Kim HG, et al. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int J Antimicrob Agents 2009; 33:149-153.
43. Martinez LR, Mihu MR, Tar M, et al. Demonstration of antibiofilm and antifungal efficacy of chitosan against candidal biofilms, using an in vivo central venous catheter model. J Infect Dis 2010; 201:1436-1440.
44. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or mica-fungin catheter lock solutions on Candida albicans biofilm growth. J Anti-microb Chemother 2008; 62:153-155.
45. Buckler BS, Sams RN, Goei VL, et al. Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy. Pediatr Infect Dis J 2008; 27:762-764.
46. Angel-Moreno A, Boronat M, Bolanos M, et al. Candida glabrata fungemia cured by antibiotic-lock therapy: case report and short review. J Infect 2005; 51:e85-87.
47. Nett JE, Sanchez H,Cain MT, et al. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis 2010; 202:171-175.